Inhibitor Therapeutics (INTI) Stock Chart & Stock Price History $0.05 0.00 (0.00%) As of 07/24/2025 Add Compare Share Share Chart Stock AnalysisChartEarningsHeadlinesSEC FilingsShort InterestBuy This Stock Inhibitor Therapeutics Stock Price Performance The Inhibitor Therapeutics (INTI) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 22.14%, with a year-to-date return of -8.99%. In the past month, the stock has increased 14.20%, reflecting recent market activity. As of the latest close, Inhibitor Therapeutics traded at $0.05 with a market cap of $9.44 million and volume of 75 shares. Five years ago, the stock traded at $0.08, representing a 30.67% decrease over that period. At the time, it had a market cap of $29.27 million and a volume of 2,500 shares. Receive INTI Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Inhibitor Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance+21.56%1 Month Performance+14.20%3 Month Performance-8.22%Year-To-Date Performance-8.99%1 Year Performance-22.14%5 Year Performance-30.67% INTI Stock Chart for Saturday, July, 26, 2025 INTI Chart by TradingView Inhibitor Therapeutics Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization07/25/2025$0.05$0.05$0.05$0.0575 shs$9.44 million07/24/2025$0.05$0.05$0.05$0.057,000 shs$9.44 million07/23/2025$0.05$0.05$0.05$0.057,000 shs$9.44 million07/22/2025$0.05$0.05+21.56%$0.05$0.057,000 shs$9.44 million07/21/2025$0.05$0.05-6.25%$0.05$0.0524,000 shs$7.77 million07/18/2025$0.05$0.05$0.05$0.045,080 shs$8.28 million07/17/2025$0.05$0.05-2.04%$0.05$0.045,080 shs$8.28 million07/16/2025$0.05$0.05$0.05$0.05500 shs$8.46 million07/15/2025$0.05$0.05$0.05$0.05500 shs$8.46 million07/14/2025$0.05$0.05-2.00%$0.05$0.05500 shs$8.46 million Get the Latest News and Ratings for INTI and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Inhibitor Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 07/11/2025$0.05$0.05$0.05$0.04232 shs$8.63 million07/10/2025$0.04$0.05+13.90%$0.05$0.04232 shs$8.63 million07/09/2025$0.04$0.04$0.04$0.049,800 shs$7.58 million07/08/2025$0.05$0.04-8.54%$0.04$0.049,800 shs$7.58 million07/04/2025$0.05$0.05$0.05$0.051,500 shs$8.28 million07/03/2025$0.05$0.05$0.05$0.051,500 shs$8.28 million07/02/2025$0.04$0.05+14.83%$0.05$0.051,500 shs$8.28 million07/01/2025$0.04$0.04$0.04$0.043,300 shs$7.21 million06/30/2025$0.05$0.04-10.87%$0.04$0.043,300 shs$7.21 million06/27/2025$0.05$0.05-2.09%$0.05$0.044,000 shs$8.09 million06/26/2025$0.04$0.05+10.37%$0.05$0.051,000 shs$8.27 million Related Companies FibroGen Stock Chart Kezar Life Sciences Stock Chart Clene Stock Chart HedgePath Pharmaceuticals Stock Chart OnKure Therapeutics Stock Chart Biodexa Pharmaceuticals Stock Chart Rein Therapeutics Stock Chart Provectus Biopharmaceuticals Stock Chart Estrella Immunopharma Stock Chart Dyadic International Stock Chart Receive INTI Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Inhibitor Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (OTCMKTS:INTI) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredElon Musk: “This will transform civilization as we know it.”Robots are no longer science fiction — they’re the next trillion-dollar megatrend. According to Forbes, by ...Weiss Ratings | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibitor Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibitor Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
